Submit a Comment

Print

E-mail

CHAPEL HILL, N.C. — Lantibio and TRB Chemedica have signed a licensing agreement with a subsidiary of Alcon for the U.S. development, marketing and manufacturing of a topical eye drop treatment for dry eye syndrome, the companies announced in a press release.

The product consists of a TRB-patented formulation of sodium hyaluronate that contains essential ions, which is currently in an ongoing, multicenter phase 3 study being conducted by a subsidiary of Lantibio under the U.S. Food and Drug Administration's Special Protocol Assessment program, the release said.

Under the terms of the agreement, Lantibio will conduct the development program, including filing a new drug application with the FDA. Alcon will assume responsibility for subsequent marketing, sales and manufacturing for the U.S. market. Alcon will also be responsible for up-front and development milestone payments, as well as royalties to be paid to Lantibio and TRB Chemedica once the drug reaches the market, according to the release.

Story continues below↓

Lantibio expects to file the new drug application in 2008, the release said.